Tags

Type your tag names separated by a space and hit enter

Invasive Pneumococcal Disease in Patients With Sickle Cell Disease.
J Pediatr Hematol Oncol 2017; 39(5):341-344JP

Abstract

BACKGROUND

Patients with sickle cell disease (SCD) are at risk of fatal sepsis with encapsulated bacteria, such as Streptococcus pneumoniae, because of the inherent autosplenectomy that occurs in SCD. This risk is thwarted with oral penicillin prophylaxis during the first 5 years of life, and with stringent vaccination against S. pneumoniae alongside routine childhood immunization. But compared with the general African American pediatric population, the rate of invasive pneumococcal disease (IPD) in patients with SCD still remains high, resulting in hospitalization and fatality.

METHODS

Patients with SCD who developed IPD from 2004 up to 2013 were identified using microbiology records. Descriptive analysis of presence of risk factors for IPD, type of SCD, pneumococcal vaccination and prophylaxis status, clinical presentation, microbiological data, and the outcome of IPD was performed.

RESULTS

Eight patients with SCD developed IPD (7 bacteremia and 1 respiratory tract infection). Three of the 8 isolates underwent serotype analysis (15 C in 2 and 15A in 1), none covered with the current vaccination program. One patient had fatal outcome (15A).

CONCLUSIONS

Breakthrough cases of IPD may involve nonvaccine isolates, and seem to occur after 5 years of age when oral penicillin prophylaxis has been terminated.

Authors+Show Affiliations

*The Carman and Ann Adams Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Detroit †Pediatric Hematology and Oncology §Pediatric Infectious Diseases, Detroit ∥Department of Microbiology, Detroit Medical Center University Laboratories, Detroit, MI ‡Department of Pediatrics, Saint Louis University, Cardinal Glennon Children's Hospital, Saint Louis, MO.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28538501

Citation

Navalkele, Pournima, et al. "Invasive Pneumococcal Disease in Patients With Sickle Cell Disease." Journal of Pediatric Hematology/oncology, vol. 39, no. 5, 2017, pp. 341-344.
Navalkele P, Özgönenel B, McGrath E, et al. Invasive Pneumococcal Disease in Patients With Sickle Cell Disease. J Pediatr Hematol Oncol. 2017;39(5):341-344.
Navalkele, P., Özgönenel, B., McGrath, E., Lephart, P., & Sarnaik, S. (2017). Invasive Pneumococcal Disease in Patients With Sickle Cell Disease. Journal of Pediatric Hematology/oncology, 39(5), pp. 341-344. doi:10.1097/MPH.0000000000000858.
Navalkele P, et al. Invasive Pneumococcal Disease in Patients With Sickle Cell Disease. J Pediatr Hematol Oncol. 2017;39(5):341-344. PubMed PMID: 28538501.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Invasive Pneumococcal Disease in Patients With Sickle Cell Disease. AU - Navalkele,Pournima, AU - Özgönenel,Bülent, AU - McGrath,Eric, AU - Lephart,Paul, AU - Sarnaik,Sharada, PY - 2017/5/26/pubmed PY - 2017/9/25/medline PY - 2017/5/25/entrez SP - 341 EP - 344 JF - Journal of pediatric hematology/oncology JO - J. Pediatr. Hematol. Oncol. VL - 39 IS - 5 N2 - BACKGROUND: Patients with sickle cell disease (SCD) are at risk of fatal sepsis with encapsulated bacteria, such as Streptococcus pneumoniae, because of the inherent autosplenectomy that occurs in SCD. This risk is thwarted with oral penicillin prophylaxis during the first 5 years of life, and with stringent vaccination against S. pneumoniae alongside routine childhood immunization. But compared with the general African American pediatric population, the rate of invasive pneumococcal disease (IPD) in patients with SCD still remains high, resulting in hospitalization and fatality. METHODS: Patients with SCD who developed IPD from 2004 up to 2013 were identified using microbiology records. Descriptive analysis of presence of risk factors for IPD, type of SCD, pneumococcal vaccination and prophylaxis status, clinical presentation, microbiological data, and the outcome of IPD was performed. RESULTS: Eight patients with SCD developed IPD (7 bacteremia and 1 respiratory tract infection). Three of the 8 isolates underwent serotype analysis (15 C in 2 and 15A in 1), none covered with the current vaccination program. One patient had fatal outcome (15A). CONCLUSIONS: Breakthrough cases of IPD may involve nonvaccine isolates, and seem to occur after 5 years of age when oral penicillin prophylaxis has been terminated. SN - 1536-3678 UR - https://www.unboundmedicine.com/medline/citation/28538501/Invasive_Pneumococcal_Disease_in_Patients_With_Sickle_Cell_Disease L2 - http://Insights.ovid.com/pubmed?pmid=28538501 DB - PRIME DP - Unbound Medicine ER -